- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05563935
Function-metabolism Coupling in Decision-making Confidence Neural Network of Obsessive-compulsive Disorder
A Study of Function-metabolism Coupling in Decision-making Confidence Neural Network of Obsessive-compulsive Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OCD shows various abnormalities in cognitive function. Decision-making confidence is a burgeoning research focus on cognitive abnormality of OCD. Gamma-aminobutyric acid (GABA) is a type of inhibitory amino acid. Some studies have indicated that GABA shows metabolic abnormality in OCD.
Repetitive transcranial magnetic stimulation (rTMS) is a safe and noninvasive treatment for OCD. This study intends to explore the differences of the function-metabolism coupling in decision-making confidence neural network between OCD and HC. And investigating the dynamic changes of the function-metabolism coupling after rTMS treatment (6 weeks) for OCD is another goal.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Qihui Guo
- Phone Number: 15221398831
- Email: guoharry@qq.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Shanghai Mental Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
OCD group:
- Age between 18 and 50 years.
- Satisfied with the diagnostic criteria for OCD in DSM-V.
- Taking medication or unmedication stably for 8 weeks or drug-naive.
- YBOCS score ≥16.
- Education level was limited to above middle school.
- Has sufficient audiovisual skills to complete the necessary examinations for the study.
- Right-handed (this criterion is for fMRI subjects only).
- Subjects understood the study and signed informed consent.
HC group:
- Match with the OCD group on age, gender, education years.
- Unsatisfied with the diagnostic criteria for any mental disorder in DSM-V.
- No history of taking psychotropic drugs.
- No family genetic history of mental disorder.
- Has sufficient audiovisual skills to complete the necessary examinations for the study.
- Right-handed (this criterion is for fMRI subjects only).
- Subjects understood the study and signed informed consent.
Exclusion Criteria:
OCD group:
- Satisfied with the diagnostic criteria for a mental disorder in DSM-V other than OCD.
- HAMD-17 score ≥ 17.
- IQ < 70.
- Obsessive-compulsive symptoms were too severe to participate in the experiment.
- Hoarding symptom.
- High risk of negative thought and suicide.
- Severe central system or physical disease or drug abuse.
- Pregnant women or women that getting ready for being pregnant and lactating.
- With metal implants in the body, such as pacemakers, intracranial silver clips, metal dentures, arterial stents, arterial clips, joint metal fixation, or other metal implants, etc. (this criterion is for fMRI subjects only)
HC group:
- High risk of negative thought and suicide.
- HAMD-17 score ≥ 17.
- IQ < 70.
- Severe central system or physical disease or drug abuse.
- Pregnant women or women that getting ready for being pregnant and lactating.
- With metal implants in the body, such as pacemakers, intracranial silver clips, metal dentures, arterial stents, arterial clips, joint metal fixation, or other metal implants, etc. (this criterion is for fMRI subjects only)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: OCD group
OCD patients will receive rTMS treatment for 6 weeks.
|
The OCD group will receive rTMS treatment for 6 weeks.
There are 5 rTMS treatments per week (Monday to Friday), and 30 rTMS treatments in total.
Treatment is administered by Ma GPro X100 device (Maga Venture) with Cool-DB80 coil.
Detailed parameters of rTMS: intensity of stimulus is 120% RMT; the frequency of trains is 1Hz and the number of pulses is 1; no intertrain intervals and the pulses number is 1000.
|
No Intervention: HC group
Health control will not receive any treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Yale-Brown Obsessive-Compulsive Scale (YBOCS)
Time Frame: Change from Baseline at 6weeks
|
YBOCS is compiled by Goodman in the United States and contains 10 items to assess the severity of obsessive thoughts and compulsive behavior.
The scoring method adopts a five-point scale of 0-4 points, and the total score range is 0-40 points, which has good reliability and validity.
|
Change from Baseline at 6weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hamilton Depression Scale (HAMD-17)
Time Frame: Change from Baseline at 6weeks
|
It is one of the most widely used examiner-rating depression scales, which contains 17 items.
It is used to measure the severity of depression and its change in treatment.
The total score range is 0-59, and a lower score means a better outcome.
|
Change from Baseline at 6weeks
|
Hamilton Anxiety Scale (HAMA-14)
Time Frame: Change from Baseline at 6weeks
|
It is one of the most widely used examiner-rating anxiety scales, which contains 14 items.
It is used to measure the severity of anxiety and its change in treatment.
The scoring method adopts a five-point scale of 0-4 points.
The total score range is 0-56 and a lower score means a better outcome.
|
Change from Baseline at 6weeks
|
Florida Obsessive Compulsive Inventory (FOCI)
Time Frame: Change from Baseline at 6weeks
|
FOCI, a self-rating scale, is used to assess the severity of obsessive-compulsive symptoms within one month, which contains 20 items.
The first 15 items are evaluated the symptoms by yes and no, and the last 5 items are evaluated the severity of symptoms on 0-4 five-point scale.
The total score range is 0-20 and a lower score means a better outcome.
|
Change from Baseline at 6weeks
|
Obsessive Belief Questionnaire (OBQ-44)
Time Frame: Change from Baseline at 6weeks
|
It is a self-rating scale to assess the severity of the obsessive belief, which contains 44 items.
The scoring method adopts a seven-point scale of 1-7 points.
The total score range is 44-308 and a lower score means a better outcome.
|
Change from Baseline at 6weeks
|
State-Trait Anxiety Inventory (STAI)
Time Frame: Change from Baseline at 6weeks
|
It is one of the most widely used self-rating anxiety scales, which contains 40 items.
The first 20 items are used to measure the state anxiety and the last 20 items are used to measure trait anxiety.
The scoring method adopts a four-point scale of 1-4 points.
Both the total score range of state anxiety and trait anxiety are 20-80 and a lower score means a better outcome.
|
Change from Baseline at 6weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decision-making confidence
Time Frame: Change from Baseline at 6weeks
|
The decision-making confidence is measure by randomized dot motion (RDM) task with a self-reported confidence scale (1-4 points).
And a lower score means a lower decision-making confidence.
|
Change from Baseline at 6weeks
|
The distribution and level of GABA in the brain
Time Frame: Change from Baseline at 6weeks
|
Using the SPICE (an advanced MRI technology) to measure the distribution and level of gamma-aminobutyric acid (GABA) in the brain.
The change of GABA metabolism will be observed during treatment.
|
Change from Baseline at 6weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Qing Fan, Doctor, Shanghai Mental Health Center
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-51
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-Compulsive Disorder
-
Anne Katrine PagsbergCopenhagen Trial Unit, Center for Clinical Intervention Research; Danish Research...Active, not recruitingObsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceDenmark
-
Baylor College of MedicineRecruitingObsessive-Compulsive Disorder | Cognitive Behavioral Therapy | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Chaim HuijserLevvelRecruitingObsessive-Compulsive Disorder | Anxiety Disorders and Symptoms | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceNetherlands
-
Stanford UniversityCompletedObsessive Compulsive DisorderUnited States
-
NYU Langone HealthCompletedObsessive Compulsive DisorderUnited States
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
Boston University Charles River CampusCompletedObsessive Compulsive DisorderUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedObsessive Compulsive DisorderUnited States
-
Karolinska InstitutetCompletedObsessive Compulsive DisorderSweden
-
Roseli ShavittCompleted
Clinical Trials on Repetitive transcranial magnetic stimulation
-
State University of New York - Upstate Medical...RecruitingHeadache | Brain Concussion | Mild Traumatic Brain Injury | Post-Concussion SymptomsUnited States
-
Xuzhou Central HospitalThe Affiliated Hospital of Xuzhou Medical UniversityNot yet recruitingFunctional Magnetic Resonance Imaging | Executive Function Disorder
-
Al-Azhar UniversityCompleted
-
Guangzhou Psychiatric HospitalCompletedCognitive Impairment | Bipolar Disorder | RelapseChina
-
Fatih Sultan Mehmet Training and Research HospitalCompletedFailed Back Surgery Syndrome
-
Veterans Medical Research FoundationUnited States Department of DefenseCompletedHeadache | Gulf War SyndromeUnited States
-
Yi YangRecruitingTranscranial Magnetic StimulationChina
-
Yi YangRecruitingTranscranial Magnetic StimulationChina
-
First Affiliated Hospital of Zhejiang UniversityCompletedBipolar DisorderChina
-
Izmir Katip Celebi UniversityCompletedPost-stroke Shoulder PainTurkey